BioSpace News Archive

Genetown

Agenus to Participate in B. Riley Healthcare Conference

Agenus Inc. today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming B. Riley Virtual Healthcare Conference on January 18th.

January 4, 2024
·
1 min read
Drug Development

Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs

Cybin Inc. today outlined its recent positive Phase 2 CYB003 topline results in MDD and near-term milestones across its clinical-stage deuterated psilocybin and dDMT programs in development for the treatment of multiple mental health conditions.

January 4, 2024
·
10 min read
Business

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies

Boehringer Ingelheim and 3T Biosciences (“3T”) today announced they have entered into a new strategic collaboration and licensing agreement focused on discovering and developing next-generation life-changing cancer immunotherapies.

January 4, 2024
·
3 min read
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site

ITM Isotope Technologies Munich SE announced the receipt of the Radioactive Material Handling License for the company’s NOVA facility, the world’s largest Lutetium-177 production site.

January 4, 2024
·
3 min read
BioMidwest

ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

ZyVersa Therapeutics, Inc. announces that Noble Capital Markets has initiated company-sponsored equity research coverage.

January 4, 2024
·
5 min read
Business

Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)

Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®.

January 4, 2024
·
4 min read
Biotech Bay

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system, inflammatory and cardiometabolic diseases, provided program updates and announced upcoming key milestones.

January 4, 2024
·
9 min read
Genetown

Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference

Solid Biosciences Inc. today announced that Bo Cumbo, President and Chief Executive Officer, will present at the J.P Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:45 am PT.

January 4, 2024
·
1 min read
BioForest

Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates

Cocrystal Pharma, Inc. provides an update on the clinical development of its oral first-in-class pan-norovirus and pan-coronavirus dual protease inhibitor CDI-988 and its oral PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A.

January 4, 2024
·
5 min read
Pharm Country

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

Madrigal Pharmaceuticals, Inc. today announced five health economics abstracts being presented at the NASH-TAG Conference, taking place from January 4-6, 2024 in Park City, Utah.

January 4, 2024
·
11 min read